Holen Sie sich die Stockscreener-App
129.16
0.02%
-0.02
Vorhandelsmarkt:
129.75
0.59
+0.46%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$129.18
Offen:
$130.09
24-Stunden-Volumen:
13.41M
Relative Volume:
2.14
Marktkapitalisierung:
$160.36B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
17.57
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
-3.92%
1M Leistung:
-3.24%
6M Leistung:
+6.55%
1J Leistung:
+16.93%
1-Tages-Spanne:
$128.92
$131.66
1-Wochen-Bereich:
$127.07
$133.99
52-Wochen-Spanne:
$104.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
129.16 | 160.39B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,131.42 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.77 | 549.25B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.23 | 397.42B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.79 | 297.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.95 | 281.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now? - Insider Monkey
Gilead Sciences, Inc. $GILD Shares Purchased by ING Groep NV - MarketBeat
Los Angeles Capital Management LLC Sells 676,504 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Capital World Investors Has $5.26 Billion Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Capital Research Global Investors - MarketBeat
Capital International Inc. CA Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
DB&C Advisors LLC Invests $1.57 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD), Lakefront Biotherapeutics Acquire Ouro Medicines to Advance Autoimmune Pipeline - Yahoo Finance
Westfield Capital Management Co. LP Takes $5.10 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Vise Technologies Inc. Purchases 11,294 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
PBU The Pension Fund of Early Childhood & Youth Educators Purchases Shares of 95,333 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by BI Asset Management Fondsmaeglerselskab A S - MarketBeat
111 Capital Sells 7,913 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands - TradingView
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $168 - Moomoo
Gilead Sciences, Lakefront Biotherapeutics Acquire Ouro Medicines - Contract Pharma
Harvest Fund Management Co. Ltd Acquires 13,385 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Prudential PLC Trims Stake in Gilead Sciences, Inc. $GILD - MarketBeat
GILD: Gilead Supports South Africa's Launch of Lenacapavir for H - GuruFocus
Gilead applauds efforts to launch lenacapavir for HIV prevention in South Africa - The Pharma Letter
Daiwa Securities Group Inc. Has $40.43 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Cibc World Market Inc. Buys 97,779 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Arrowpoint Investment Partners Singapore Pte. Ltd. Invests $2.38 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Key facts: Gilead completes $7.8B Arcellx buy; closes Ouro Medicines deal - TradingView
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa - Business Wire
Gilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSN
Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - Stocktwits
US FDA approves Gilead's drug for deadly liver infection - MSN
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline - TradingView
Gilead Sciences (GILD) Has an HIV-and-Oncology Bridge That Makes the Base Business Harder to Ignore - AlphaStreet
Gilead and Lakefront complete Ouro Medicines acquisition - Investing.com
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE - The Manila Times
Gilead’s Livdelzi approved by NICE for PBC - The Pharma Letter
TD Asset Management Inc Sells 67,251 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead eyes PBC expansion for Livdelzi on positive one-year data - Clinical Trials Arena
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
GILD Reports Positive Results From Late-Stage Liver Disease Study - Yahoo Finance
With Cencora pact, Gilead looks to grow CAR-T treatment center network - Fierce Pharma
IDEAL Data Expands Gilead’s Livdelzi Evidence Into Lower-ALP PBC Population - Citeline News & Insights
Scotiabank Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $177 - Moomoo
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Weakness - Yahoo Finance
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance Singapore
Gilead Data On Livdelzi And Trodelvy Points To Broader Future Mix - simplywall.st
Marble Wealth LLC Acquires Shares of 9,588 Gilead Sciences, Inc. $GILD - MarketBeat
Natixis Advisors LLC Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
CIBC Asset Management Inc Buys 128,992 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. Acquires Significant Stake in Assembly Biosciences Inc. - GuruFocus
Gilead Sciences, Inc. Acquires Significant Stake in Assembly Bio - GuruFocus
Insider Sell: Daniel O'Day Sells 15,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
How Investors Are Reacting To Gilead Sciences (GILD) Expanding Liver And Oncology Drug Footprint - Yahoo Finance
Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O'day Sells 15,000 Shares - MarketBeat
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.36%
1.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):